FY2017 EPS Estimates for Tetraphase Pharmaceuticals, Inc. Cut by Analyst (TTPH)

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Equities research analysts at Gabelli dropped their FY2017 earnings per share (EPS) estimates for shares of Tetraphase Pharmaceuticals in a research note issued on Thursday. Gabelli analyst K. Kedra now anticipates that the biopharmaceutical company will post earnings per share of ($2.95) for the year, down from their previous estimate of ($2.45). Gabelli also issued estimates for Tetraphase Pharmaceuticals’ FY2018 earnings at ($1.75) EPS, FY2019 earnings at ($1.55) EPS, FY2020 earnings at ($1.15) EPS and FY2021 earnings at ($0.95) EPS.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. During the same period last year, the firm earned ($0.47) earnings per share. The company’s quarterly revenue was up 28.2% compared to the same quarter last year. TRADEMARK VIOLATION WARNING: This story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/11/fy2017-eps-estimates-for-tetraphase-pharmaceuticals-inc-cut-by-analyst-ttph.html.

Several other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. BMO Capital Markets boosted their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $12.96.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 7.20 on Monday. The stock has a 50 day moving average of $6.88 and a 200-day moving average of $7.27. The company’s market capitalization is $367.58 million. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93.

In related news, insider Jacques Dumas sold 7,155 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. AXA bought a new stake in Tetraphase Pharmaceuticals during the 2nd quarter valued at $132,000. Citadel Advisors LLC raised its holdings in Tetraphase Pharmaceuticals by 18.6% in the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after purchasing an additional 2,496 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in Tetraphase Pharmaceuticals in the 2nd quarter worth $147,000. Voya Investment Management LLC raised its holdings in Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares in the last quarter. Finally, UBS Group AG raised its holdings in Tetraphase Pharmaceuticals by 2.3% in the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares in the last quarter. Institutional investors own 41.73% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-res

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Equities research analysts at Gabelli dropped their FY2017 earnings per share (EPS) estimates for shares of Tetraphase Pharmaceuticals in a research note issued on Thursday. Gabelli analyst K. Kedra now anticipates that the biopharmaceutical company will post earnings per share of ($2.95) for the year, down from their previous estimate of ($2.45). Gabelli also issued estimates for Tetraphase Pharmaceuticals’ FY2018 earnings at ($1.75) EPS, FY2019 earnings at ($1.55) EPS, FY2020 earnings at ($1.15) EPS and FY2021 earnings at ($0.95) EPS.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. During the same period last year, the firm earned ($0.47) earnings per share. The company’s quarterly revenue was up 28.2% compared to the same quarter last year. TRADEMARK VIOLATION WARNING: This story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/11/fy2017-eps-estimates-for-tetraphase-pharmaceuticals-inc-cut-by-analyst-ttph.html.

Several other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 5th. BMO Capital Markets boosted their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $12.96.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 7.20 on Monday. The stock has a 50 day moving average of $6.88 and a 200-day moving average of $7.27. The company’s market capitalization is $367.58 million. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93.

In related news, insider Jacques Dumas sold 7,155 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. AXA bought a new stake in Tetraphase Pharmaceuticals during the 2nd quarter valued at $132,000. Citadel Advisors LLC raised its holdings in Tetraphase Pharmaceuticals by 18.6% in the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after purchasing an additional 2,496 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in Tetraphase Pharmaceuticals in the 2nd quarter worth $147,000. Voya Investment Management LLC raised its holdings in Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares in the last quarter. Finally, UBS Group AG raised its holdings in Tetraphase Pharmaceuticals by 2.3% in the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares in the last quarter. Institutional investors own 41.73% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply